Compare Boston Beer Company Inc (SAM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Boston Beer Company Inc trades at $170.75 (market cap $1.88B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 64.9× Boston Beer Company Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| SAM | VRTX | |
|---|---|---|
Market Cap | $1.88B | $121.95B |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $529.59 |
52-Week Low | $161.08 | $366.54 |
Enterprise Value | $1.75B | $116.69B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
